Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre‐specified patient subgroups in the Effisayil 1 study

• DOI: 10.1111/exd.14824
• Publication Date: 2023-05-04T12:53:09Z
• Authors: A. D. Burden; Y. Okubo; M. Zheng; D. Thaçi; P. van de Kerkhof; N. Hu; M. Quaresma; C. Thoma; S. E. Choon
• Keywords: Generalized pustular psoriasis; Clinical endpoint; Demographics

Abstract Effisayil 1 was a multicentre, randomized, double‐blind, placebo‐controlled study of the anti‐interleukin (IL)‐36 receptor monoclonal antibody, spesolimab, in patients presenting with generalized pustular psoriasis (GPP) flare. Previously published data from this revealed that within week, rapid and skin clearance were observed receiving spesolimab versus placebo. In pre‐specified subgroup analysis, efficacy evaluated according to patient demographic clinical characteristics at baseline ( n = 35) or placebo 18) on Day 1. Efficacy by assessed achievement primary endpoint (Generalized Pustular Psoriasis Physician Global Assessment [GPPGA] pustulation subscore 0 Week 1) key secondary (GPPGA total score 1). Safety Spesolimab found be efficacious had consistent favourable safety profile GPP flare, regardless demographics baseline.